Item 2.01 - Completion of Acquisition or Disposition of Assets: Illumina completed its acquisition of Standard BioTools' aptamer-based and functional proteomics business on January 30, 2026, including all shares of SomaLogic, Inc. and interests in Sengenics entities, for a cash purchase price of $350 million subject to customary adjustments. Contingent Consideration: The Purchase Agreement…

Our analysis rates this filing CAUTIOUS. Illumina's acquisition of SomaLogic represents a strategically sound but operationally complex expansion into proteomics. The elevated concern level (6.8/10) reflects the material execution risks inherent in integrating a $350M+ acquisition while…

Concern level: HIGH (6.8/10). Key factors: One critical high-severity risk identified: Integration Risk of Major Acquisition (severity 7/10) with $350M upfront capital deployment plus $75M contingent payments; Risk trend is INCREASING overall, signaling deteriorating risk profile; Multiple new execution risks explicitly disclosed in forward-looking statements: proteomics market adoption…

Notable risk changes: Completed $350M acquisition of SomaLogic with up to $75M in contingent milestone payments - represents significant capital deployment and balance sheet impact; success dependent on integration execution and market adoption; Explicit forward-looking statement risks now include proteomics market growth, customer relationship management, manufacturing complexity, and product launch execution -…

The model predicts ILMN will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.